Navigation Links
PharmaVentures Helps Secure Investor for Former MSD Research Site

OXFORD, England, January 19, 2012 /PRNewswire/ --

PharmaVentures announced today that it was delighted to act as transaction advisor to MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the former MSD research facility in Newhouse, Lanarkshire.

The deal follows exceptional collaborative working between MSD, the Scottish Life Sciences community and the Scottish Government.

The transfer of this research facility from MSD to BioCity Scotland unlocks over 130,000 sq ft of purpose-built laboratories and offices on the 23 acre site capable of supporting drug discovery and development for growing bioscience, pharmaceutical, med-tech and healthcare companies.  

Fintan Walton, Chief Executive of PharmaVentures, said: "PharmaVentures is delighted to have worked with MSD in finding a new investor like BioCity Scotland to turn the former MSD research facility into an incubator for growing innovative enterprises. This is a fantastic outcome for the site and for the UK Life Science industry as a whole, creating new job opportunities from start-up companies and providing the infrastructure to support expansion of existing businesses."

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures:

PharmaVentures ( is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of their track record of successful outcomes, resulting from their unique insight into the world of deal making, their internationally recognised analytical and valuation capabilities, their own proprietary deal making database PharmaDeals®  (, containing over 42,000 deal records, and their extensive business relationship network and our outstanding success in M&A transactions.

Over the years PharmaVentures has built considerable experience in the M&A field including the divestment of manufacturing and R&D businesses most of which have led to both the protection and the creation of jobs.

Their services cover:

  • Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
  • Licensing (in and out-licensing)
  • M&A (companies & assets)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:

Dr Fintan Walton, Chief Executive, PharmaVentures

SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. PharmaVentures Appoints Andy Smith as Head of Corporate Finance
3. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
4. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
5. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
8. Software Helps Research Facilities Meet New NIH Financial Conflict of Interest (FCOI) Requirements
9. FindTheBest Helps Parents Find Cord Blood Banks
10. Mirage-effect helps researchers hide objects
11. The Vitality Group Helps U.S. Businesses Navigate New Legal Environment for Health and Wellness Programs
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):